Board of Directors



Bernard Gilly, Chairman

Bernard Gilly has over 20 years of experience in the financial and pharmaceutical sectors, and as an entrepreneur. He was Vice-President R&D for 5 years at Pasteur Mérieux Connaught (now Sanofi Pasteur). Afterwards, he became the CEO of Transgene from 1992 to 2000, heading the Company's listing and raising over $120 million. He later joined Sofinnova Partners in Paris (2000-2005). In 2005, he founded and became the CEO of Fovea Pharmaceuticals. After Fovea was acquired by Sanofi in 2009, he became Executive Vice President of the Ophthalmology Division of Sanofi. Lastly, he founded Pixium Vision in 2011.

Khalid Ishaque, CEO

Khalid Ishaque has over 20 years of experience in the medical technology sector. He joined Pixium Vision in 2014 after having spent 17 years with the Boston Scientific in various commercial and business development roles, and most recently as General Manager of International Neuromodulation division commercialising Spinal Cord and Deep Brain Stimulation systems for chronic pain and movement disorders. Before joining Boston Scientific in 1997, he worked for Becton Dickinson. He received his Master in engineering from Cranfield Institute of Technology in the United Kingdom and Master in international Economics and Management from SDA Bocconi University in Italy.

Robert J.W. ten Hoedt, Director

Mr. ten Hoedt is currently the Executive Vice President & President, Europe, Middle East & Africa (EMEA) of Medtronic Plc. and a member of its Executive Committee. Mr. ten Hoedt has been with Medtronic since 1991 and has over 25 years of experience in the medical device industry. Leading up to this position, he has held several different leadership roles in Medtronic. He led the Cardio-Vascular business for Europe & Central Asia and the Gastro-Urology business on a global basis before which he ran the wholly-owned Medtronic subsidiary Company, Vitatron. Prior to Medtronic, he has held positions in medical technology companies such as Arjo Hospital Equipment and Polystan Benelux and also ran his own Distributor Company for several years. He is the Chairman of the Board of MedTech Europe, the Association representing the medical technology industry in Europe. He holds a degree in Commercial Economy from the H.E.A.O. and a Masters in Marketing from the NIMA Business School in the Netherlands.

James A. Reinstein, Director

James A. Reinstein previously held the position of Senior Vice President and Chief Commercial Officer for Cyberonics, a neurostimulation company focused on the treatment of epilepsy and depression. At Cyberonics, he led a commercial turn around by growing revenues from approximately $100 million in 2007 to over $200 million within four years. Mr. Reinstein joined Cyberonics after a 17-year career with Boston Scientific Corp., where he held general management and commercial leadership positions in Europe, Latin America and Asia. He built strong teams within those operations with solid competencies in sales, marketing, government affairs, reimbursement, logistics and finance. After earning a Bachelor’s Degree in Business Administration from the Terry College of Business at the University of Georgia in Athens, Mr. Reinstein spent four years in sales and sales management roles with Procter & Gamble. Mr. Reinstein also completed General Management studies at INSEAD in Fontainebleau, France.

Timothy J. Haines, Director

Timothy J. Haines, a partner in Abingworth LLP, has over 25 years of international management experience in the life sciences industry. Throughout his career, he held a number of other management positions in companies in the life sciences sector in the US and Europe. He is a former director of the Biotech Industry Association and sits on the Venture Capital Committee of the British Venture Capital Association and the Wellcome Trust/ NHS Health Innovation Challenge Fund. Timothy J. Haines holds a BSc from Exeter University and an MBA from INSEAD.

Antoine Papiernik, permanent representative of Sofinnova Partners, Director

Antoine Papiernik is a partner at Sofinnova Partners, which he joined in 1997. He has invested in numerous companies in Europe, such as Actelion, Addex, Orexo, NovusPharma (which was sold to CTI), Movetis (which was sold to Shire) and Stentys, for which he is also an active board member. He has also invested in Cotherix (originally listed on NASDAQ, then sold to Actelion), CoreValve (sold to Medtronic) and Fovea (sold to Sanofi Aventis). He is also an investor in, and sits on the boards of directors of, MD Start, EOS, Mainstay, Recor, Auris Medical and Shockwave Medical. Mr Papiernik earned an MBA from the Wharton School of Business at the University of Pennsylvania. In 2011 and 2012, he was included in Forbes magazine’s Midas list of the best venture capitalists in the world.

Chahra Louafi, permanent representative of Bpifrance Investissement, Director

Chahra Louafi is an investment director and head of the biotherapies and rare diseases fund of Bpifrance (formerly CDC Entreprises). Before joining CDC Entreprises in 2001, she was in charge of project development and company creation for a private incubator that specialised in biotechnologies. She is Vice-Chairman of the supervisory board of Inserm Transfert Initiative and a member of the supervisory board of Cap Décisif Management. She also sits on the boards of directors of DBV Technologies, Sensorion, Eyevensys and MedDay.

Mailys Ferrere, Permanent Representative of Bpi France Participations

Mailys Ferrere is the Director of the Large Venture Investment pole of Bpifrance. A graduate of IEP (Institut d’Etudes Politiques) in Paris, she began her career in 1985 with the General Inspectorate of Société Générale before joining Worms Bank two years later, first as financial secretary then as originator in the equity capital markets activity. In 1993 she became Deputy Director of Client Services at Crédit National and was appointed four years later project Leader at Natexis. In 2000, she was recruited by KBC Securities as senior ECM originator. Two years later, Maylis joined Ixis and Natixis as head of midcaps in ECM origination department. From 2009 to 2013 she was director of investment at the FSI (Fond Stratégique d’Investissement).

Prof. José-Alain Sahel, Observer

Prof. Sahel is Professor, Université Pierre et Marie Curie, and Director of Institut de la Vision and Chairman of the Department of Ophthalmology at the Quinze-Vingts National Eye Hospital (Paris) and at the Rothschild Ophthalmology Foundation. He is also Professor at the Institute of Ophthalmology at the University College in London. He has been conducting pioneering research into the understanding of the pathological mechanisms involved in retinal cell degeneration. Prof. Sahel recently received awards from the US Foundation Fighting Blindness and the French “Académie des Sciences”, for his work on retinitis pigmentosa.